---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016529"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T21:25:00.196270+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024

## Summary
- Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.
- CEO salary set at $900,000 base (COO $750,000), target bonus 110% (COO 100%); equity grants valued at $6.2M total.
- Kelderman has led Diagnostics & Genomics since 2018; previously executive at Thermo Fisher and BD.
- Retention RSUs awarded to candidates Geist (~$1.05M) and Hippel (~$1.39M) vesting over two years.
- Kummeth tenure: revenue grew from $311M to $1.1B, 19 acquisitions, headcount from 800 to 3,200.

## SEC filing metadata
- accession: 0001558370-23-016529
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/tmb-20231017x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016529
- JSON: https://secwatch.observer/filing/0001558370-23-016529.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016529.txt

## Key facts
- Executive change
  Kim Kelderman was appointed as Chief Executive Officer at BIO-TECHNE Corp.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- Executive change
  Kim Kelderman was appointed as Chief Operating Officer at BIO-TECHNE Corp.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- Executive change
  Chuck Kummeth retired as Director at BIO-TECHNE Corp.
  - Action: retired
  - Role: Director
  source text: Mr. Kummeth will also retire from the Board of Directors on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- Executive change
  Chuck Kummeth was appointed as Senior Advisor at BIO-TECHNE Corp.
  - Action: appointed
  - Role: Senior Advisor
  source text: Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- Executive change
  Kim Kelderman was appointed as Director at BIO-TECHNE Corp.
  - Action: appointed
  - Role: Director
  source text: Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm
- Executive change
  Chuck Kummeth retired as Chief Executive Officer at BIO-TECHNE Corp.
  - Action: retired
  - Role: Chief Executive Officer
  source text: Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023016529/0001558370-23-016529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.